Pfizer, Inc. · NYSE:PFE
Pfizer — 2008 Annual Credit Suisse Health Care Conference
17 slides from Pfizer's conference presentation, Nov 13, 2008
Slide 1: 2008 Annual Credit Suisse Health Care Conference
2008 Annual Credit Suisse Health Care Conference Jeff Kindler Chairman and Chief Executive Officer November 13, 2008
Slide 2: Forward-Looking Statements and Non-GAAP Financial Information
Forward-Looking Statements and Non-GAAP Financial Information Discussions at this meeting will include forward-looking statements. Actual results could differ materially from those projected in the forward- looking statements. The factors that could cause actual results to differ are discussed in
Slide 3: Jeff Kindler
Jeff Kindler Chairman and Chief Executive Officer
Slide 4: Our Path Forward: Positioning Pfizer for Future Growth
Our Path Forward: Positioning Pfizer for Future Growth Maximize Revenues from Existing, New & Diverse Sources Take Advantage of Size, Scale of Pfizer Establish a Lower, More Flexible Cost Base Operate with Agility, Speed, Focus of an Entrepreneurial Organization Innovate the Business Model Drive
Slide 5: Key Commitments
Key Commitments Optimize Product Portfolio Accelerate the Pipeline Establish Smaller, More Accountable Units Expand in Emerging Markets Capitalize on Established Products Achieve Financial Guidance Align the Cost Structure with Revenues Meeting Our Commitments
Slide 6: Key Commitments: On-Track to Achieve These Commitments
Key Commitments Optimize Product Portfolio Accelerate the Pipeline e nts Establish Smaller, More Accountable Units m itm C o m he se Expand in Emerging Markets v e T c h ie t o A r a c k On-T Capitalize on Established Products Achieve Financial Guidance Align the Cost Structure with Revenues Meeting
Slide 7: Advancing Compounds in the Pipeline
Advancing Compounds in the Pipeline Pipeline as of Sept 30, 2008 Over 300 Phase 1 Phase 2 Phase 3 In Reg. Total Discovery 50 38 25 1 Projects 114 Goals (Announced March 2008) 15–20 Phase 3 starts in 2008 – 2009 24–28 Programs in Phase 3 by end of 2009 15–20 Submissions 2010 – 2012 On-Track to
Slide 8: Increasing Cost-Reduction Target
Increasing Cost-Reduction Target Achieved initial Period Cost Reduction cost-reduction goal in Qtr 3 (2006 Currency Rates) Increased goal to reduce FY 2007 $600 Million absolute adjusted total costs1 by at least $2.0 billion on a constant currency basis2 for YTD Qtr 3 2008 vs. 2006 $1.1 Billion
Slide 9: 2008 Financial Guidance
2008 Financial Guidance Guidance(4) Revenues $48.0 to $49.0 billion Decrease of at least $2 billion vs. 2006 Adjusted Total Costs(1) on a constant currency basis (5) Adjusted Cost of Sales(1) as a 15.0% to 15.5% Percentage of Revenues Adjusted SI&A Expenses(1) $14.4 to $14.7 billion Adjusted R&D Exp
Slide 10: Business Development Opportunities: Enabler for Strategic Growth Initiatives
Business Development Opportunities: Enabler for Strategic Growth Initiatives Initiatives better position us financially and structurally to execute on opportunities and realize greater shareholder value Actively assess robust and diverse options in this dynamic environment New structure empowe
Slide 11: Innovating Our Model with Smaller, More Accountable Business Units
Innovating Our Model with Smaller, More Accountable Business Units Research and Business Units Biotherapeutics & Bioinnovation Sales & Center Development Medical Marketing Customer Manufacturing Focused Supporting Functions Meeting Our Commitments
Slide 12: Innovating Our Model with Smaller, More Accountable Business Units
Innovating Our Model with Smaller, More Accountable Business Units Primary Specialty Established Emerging Animal Oncology Care Care Products Markets Health Research and Business Units Biotherapeutics & Bioinnovation Sales & Center Development Medical Marketing Customer Manufacturing Focused Supporti
Slide 13: Two Distinct, Yet Complementary Strategic Growth Initiatives
Two Distinct, Yet Complementary Strategic Growth Initiatives Established Products Emerging Markets Medicines that have lost – or are Asian, Latin American and about to lose – patent protection Eastern European countries with growing economies and Fastest growing segment of the middle-class pop
Slide 14: Significant Competitive Advantages to Execute on Our Commitments
Significant Competitive Advantages to Execute on Our Commitments More than 50% of revenues outside the U.S. Geographic Diversity Strong global footprint with experienced local leaders close to the operations and customers Diverse Sources of Revenue Focus on “Invest to Win” disease areas, estab
Slide 15: Pfizer: 2012 and Beyond
Pfizer: 2012 and Beyond Broad, Robust and Diversified Product Franchise Adjusted Operating Margins in the Mid-to-High 30%s Lean and Flexible Commercial Organization Agile Business Unit Structure Best in Class Manufacturing High Value R&D Portfolio Strong Balance Sheet Meeting Our Commitments
Slide 16: Our Path Forward
Our Path Forward Maximize Revenues from Existing, New & Diverse Sources Take Advantage of Size, Scale of Pfizer Establish a Lower, More Flexible Cost Base Operate with Agility, Speed, Focus of an Entrepreneurial Organization Innovate the Business Model Drive Greater Total Shareholder Return Meet
Slide 17: Jeff Kindler
Jeff Kindler Chairman and Chief Executive Officer
Pfizer — 2008 Annual Credit Suisse Health Care Conference on 6ix